Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s share price gapped up prior to trading on Monday . The stock had previously closed at $275.79, but opened at $291.86. Genmab A/S shares last traded at $291.86, with a volume of 184 shares traded.
Genmab A/S Trading Up 3.6%
The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. The business has a 50 day moving average of $260.49 and a 200-day moving average of $285.45. The firm has a market capitalization of $17.60 billion, a P/E ratio of 21.56 and a beta of 0.78.
About Genmab A/S
Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.
See Also
- Five stocks we like better than Genmab A/S
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
- The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
- Why Micron Is Doubling Down While the HBM Shortage Persists
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
